Full-Time

Senior Sourcing Specialist

Capital Projects

Updated on 9/4/2026

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$96.5k - $183.5k/yr

+ Short-term Incentive

Livingston, NJ, USA

Hybrid

Bachelor's

Category
Operations & Logistics (1)
Required Skills
Risk Management
Data Analysis

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Business Administration, Supply Chain Management or related field. In lieu of degree, equivalent, relevant years of experience may suffice.
  • Experience with capital expenditure (capex) projects or processes, including developing, evaluating, or managing RFP for Capital projects i.e. Construction, Production & Process Equipment etc., is preferred.
  • Minimum of 5 years of experience in procurement, supply chain, or related business or operations function.
  • Previous experience in category management, contract negotiation, and supplier relationship management.
  • Strong proficiency in Microsoft Office suite (Power Platform).
  • Fast learner comfortable navigating across a range of industries and sectors.
  • High cross-functional collaboration abilities and teamwork skills, effectively navigating and coordinating diverse team dynamics.
  • Strong interpersonal skills and emotional intelligence, facilitating empathetic interactions, effective communication, and robust relationship-building across a matrixed organization.
  • Impactful executive functioning abilities and autonomous work ethic, maintaining efficient performance in challenging situations and building consensus in decision-making.
Responsibilities
  • Partner with Procurement Manager, Category Manager and Associate Directors to execute Indirect Capital subcategory-specific procurement strategies.
  • Implement and monitor effectiveness of strategies for the relevant category, ensuring alignment with overall business goals.
  • Report on supplier process and operational health, informing Category Leaders to enable strategic decision-making, incorporating industry trends, emerging technologies, and market dynamics.
  • Monitor initiatives to drive value with category suppliers, tracking cost savings and enhancing overall procurement value.
  • Enable sustainability and environmental, social, and governance (ESG) measures, working alongside suppliers to enhance sustainable and responsible sourcing practices.
  • Execute Supplier Relationship Management (SRM) strategies, managing relationships with category suppliers and collaborating to enact creative and cutting-edge solutions that deliver on long-term business needs.
  • Implement mitigation strategies to proactively manage procurement risk across the relevant category, maintaining process and policy compliance.
  • Ensure effective project management from initiation to completion, collaborating with cross-functional teams to deliver strategic category-related projects. Assist category leaders with opportunities for process optimization and efficiency gains, executing continuous improvement programs that achieve strategic objectives.
  • Assist with the end-to-end procurement process from sourcing strategy to contract negotiation and execution, enabling negotiations with category suppliers and facilitating decisions by developing the required analysis and gathering relevant data.
  • Develop own capabilities and accumulates category expertise in accordance with individual learning path. Actively enable team goals, ensuring performance targets and objectives are delivered successfully.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Etentamig hit 74% response and 60% progression-risk reduction on September 3, 2026.
  • FDA approved Decnupaz on May 27, 2026, creating AbbVie’s first blood-cancer ADC.
  • WCLC 2026 data showed ABBV-1480 and ABBV-706 strength across lung-cancer programs.

What critics are saying

  • Imbruvica sales fell 29.4% in Q2 2026, exposing oncology erosion.
  • FDA declined trenibotE in April 2026; manufacturing fixes pushed approval into 2027.
  • CMS Botox price controls and AbbVie’s February 2026 lawsuit threaten aesthetics margins.

What makes AbbVie unique

  • AbbVie’s 2026 engine combines Skyrizi, Rinvoq, oncology, and aesthetics.
  • Apogee acquisition deepens AbbVie’s inflammatory pipeline beyond Humira replacement products.
  • AbbVie commercializes injectable biologics and ADCs across specialty, outpatient, and hospital settings.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Sep 3rd, 2026
AbbVie's etentamig shows 74% response rate in cancer trial, beating standard treatment by 28 percentage points

AbbVie's experimental cancer drug etentamig achieved a 74% overall response rate in a pivotal Phase 3 trial for relapsed or refractory multiple myeloma, significantly outperforming standard treatments at 45.7%. The study also met its progression-free-survival endpoint. The drug remains investigational pending regulatory review. AbbVie's oncology division reported $1.65 billion in second-quarter revenue, down 1.5%, representing roughly 9.7% of total sales. Venclexta grew 11.6%, whilst Imbruvica declined 29.4%. AbbVie shares traded at $260.445. The company requires new growth drivers as its existing oncology portfolio faces mixed performance. Detailed safety and durability data have not yet been disclosed.

Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Aug 29th, 2026
AbbVie acquires Apogee for $10.9B as Eli Lilly's GLP-1 drugs drive 45% revenue surge

AbbVie is acquiring Apogee Therapeutics for approximately $10.9 billion as it works to diversify beyond its core immunology portfolio. The pharmaceutical giant reported revenue of nearly $61.2 billion in FY 2025, up roughly 8.7% year-on-year, with Skyrizi and Rinvoq accounting for about 42% of sales. Eli Lilly achieved sharper growth, with revenue reaching nearly $65.2 billion in FY 2025, a 45% increase driven by GLP-1 drugs Mounjaro and Zepbound. These therapies represented roughly 56% of total revenue. Net income was approximately $20.6 billion. AbbVie's balance sheet shows a debt-to-equity ratio of negative 21x, whilst Eli Lilly's stands at roughly 1.6x. Free cash flow was nearly $17.8 billion for AbbVie and close to $9.0 billion for Eli Lilly.

Yahoo Finance
Aug 29th, 2026
AbbVie vs. Johnson & Johnson: Which healthcare stock offers better value in 2026?

AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.

Yahoo Finance
Aug 25th, 2026
AbbVie's oncology sales fall 2.4% to $1.65B as Imbruvica drops 29%

AbbVie's oncology revenues declined 2.4% year over year to $1.65 billion in Q2 2026, pressured by blood cancer drug Imbruvica, whose sales fell 29.4% to $532 million due to competitive pressure and IRA-driven pricing changes. However, growth from other products partially offset this decline. Venclexta sales rose nearly 10% to $771 million, driven by strong demand in chronic lymphocytic leukaemia. Newer products showed robust growth, with Elahere up 32% to $211 million and Epkinly increasing 48% to $103 million. Lung cancer therapy Emrelis exceeded expectations as physicians became more familiar with c-Met testing. The quarter also marked the launch of Decnupaz, AbbVie's first marketed antibody drug conjugate in haematology, following recent FDA approval for blastic plasmacytoid dendritic cell neoplasm.